Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Late diagnosis of ornithine transcarbamylase defect in three related female patients: polymorphic presentations
This fast delivery supports consistency and convenience for ongoing treatment
Heres what clinicians should consider: Patient eligibility: Typically adults with a BMI 30 or 27 with comorbidities
Patients who value FDA approval and pre-filled pen convenience may prefer brand-name at $349 monthly
Tirzepatide may provide enhanced glycemic control compared to other therapies
US$ 24.15
US$ 22.42
US$ 21.32
US$ 29.03
